<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MEPHOBARBITAL</span><br/>(me-foe-bar'bi-tal)<br/><span class="topboxtradename">Mebaral, </span><span class="topboxtradename">Methylphenobarbital<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anticonvulsant</span>; <span class="classification">barbiturate</span>; <span class="classification">sedative-hypnotic</span><br/><b>Prototype: </b>Phenobarbital<br/><b>Pregnancy Category: </b>D<br/><b>Controlled Substance: </b>Schedule IV<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>32 mg, 50 mg, 100 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Long-acting barbiturate with pharmacologic properties similar to those of phenobarbital; however, larger doses are required
         to produce comparable anticonvulsant effects
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Limits the spread of seizure activity by increasing the threshold for motor cortex stimuli. Exerts strong sedative effect,
         but relatively mild hypnotic effect.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To control grand mal and petit mal epilepsy, alone or in combination with other anticonvulsant agents, and for sedative effect
         in management of delirium tremens and other acute agitation and anxiety states.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to barbiturates; lactation. Safety during pregnancy (category D) is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Fever, hyperthyroidism, alcoholism; liver, kidney, or cardiac dysfunction.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Anticonvulsant</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400600 mg/d in divided doses<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <img src="../images/special/lesserorequal.gif"/><i>5 y</i>, 1632 mg t.i.d. or q.i.d.; <img src="../images/special/greaterorequal.gif"/><i>5 y,</i> 3264 mg t.i.d. or q.i.d.<br/><br/><span class="indicationtitle">Sedative</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 32100 mg t.i.d. or q.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <img src="../images/special/lesserorequal.gif"/><i>5 y,</i> 1632 mg t.i.d. or q.i.d.; <img src="../images/special/greaterorequal.gif"/><i>5 y,</i> 3264 mg t.i.d. or q.i.d.<br/><br/><span class="indicationtitle">Delirium Tremens</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg t.i.d. or q.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Change from other anticonvulsant by gradually tapering off the former as mephobarbital doses are increased to maintain seizure
            control.
         </li>
<li>When prescribed concurrently with phenobarbital, dose should be about one-half the amount of each used alone. When prescribed
            concurrently with phenytoin, the dose of phenytoin is usually reduced.
         </li>
<li>Reduce discontinued drug dosage gradually over 4 or 5 days to avoid precipitating seizures of status epilepticus.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Drowsiness,</span> dizziness, unsteadiness, hangover, paradoxical excitement. <span class="typehead">GI:</span> Nausea, vomiting, constipation. <span class="typehead">Body as a Whole:</span> Hypersensitivity reactions, respiratory depression. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Alcohol,</b> <span class="classification">cns depressants</span> compound CNS depression; may decrease absorption and increase metabolism of <span class="classification">oral anticoagulants</span>; increases metabolism of <span class="classification">corticosteroids</span>, <span class="classification">oral contraceptives</span>, <span class="classification">anticonvulsants</span>, <b>digitoxin,</b> possibly decreasing their effects; <span class="classification">antidepressants</span> potentiate adverse effects; <b>griseofulvin</b> decreases absorption of mephobarbitol. <span class="typehead">Herbal:</span> <b>Kava-kava,</b> <b>valerian</b> may potentiate sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 50% absorbed from GI tract. <span class="typehead">Onset:</span> 60 min. <span class="typehead">Duration:</span> 1012 h. <span class="typehead">Metabolism:</span> Metabolized in liver to phenobarbital. <span class="typehead">Elimination:</span> Excreted in urine. Alkalinization of urine or increase of urinary flow significantly increases the rate of phenobarbital excretion. <span class="typehead">Half-Life:</span> 34 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor respiratory status, especially with concurrent CNS therapy with other drugs.</li>
<li>Be prepared for paradoxical response to barbiturate therapy (i.e., irritability, marked excitement, aggression in children,
            depression, confusion) in older adults, debilitated patients, or children.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that abrupt cessation after prolonged therapy may result in withdrawal symptoms (tremulousness, weakness, insomnia,
            delirium, convulsions).
         </li>
<li>Avoid driving and potentially hazardous activities until response to drug has stabilized.</li>
<li>Do not take alcohol in any amount with a barbiturate.</li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>